
Akero Therapeutics AKRO
Quartalsbericht 2025-Q3
hinzugefügt 07.11.2025
Akero Therapeutics Betriebsaufwand 2011-2026 | AKRO
Betriebsaufwand Jährlich Akero Therapeutics
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 80.2 M | 45.7 M | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 80.2 M | 45.7 M | 62.9 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Apellis Pharmaceuticals
APLS
|
948 M | $ 20.24 | -2.22 % | $ 2.55 B | ||
|
Aptorum Group Limited
APM
|
20.7 M | $ 0.82 | -2.95 % | $ 4.47 M | ||
|
Axsome Therapeutics
AXSM
|
99.1 M | $ 165.96 | -0.25 % | $ 8.26 B | ||
|
AbCellera Biologics
ABCL
|
292 M | $ 3.74 | -2.23 % | $ 1.12 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
Burford Capital Limited
BUR
|
106 M | $ 8.49 | -2.75 % | $ 1.38 B | ||
|
Codexis
CDXS
|
31.5 M | $ 0.97 | -4.87 % | $ 71.2 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
206 M | $ 24.04 | 0.67 % | $ 2.94 B | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Corvus Pharmaceuticals
CRVS
|
23.4 M | $ 17.32 | -3.19 % | $ 832 M | ||
|
Champions Oncology
CSBR
|
12.5 M | $ 5.96 | -1.81 % | $ 81.4 M | ||
|
Daré Bioscience
DARE
|
23.5 M | $ 1.58 | -1.87 % | $ 13.4 M | ||
|
DBV Technologies S.A.
DBVT
|
121 M | $ 21.89 | -5.85 % | $ 2.12 B | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
88.2 M | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Capricor Therapeutics
CAPR
|
49.3 M | $ 25.75 | -4.13 % | $ 690 M | ||
|
Eton Pharmaceuticals
ETON
|
22.3 M | $ 17.52 | -3.47 % | $ 449 M | ||
|
Exelixis
EXEL
|
598 M | $ 40.72 | -0.76 % | $ 11.1 B | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
Amicus Therapeutics
FOLD
|
528 M | $ 14.35 | -0.1 % | $ 4.43 B | ||
|
Galectin Therapeutics
GALT
|
42.4 M | $ 2.9 | -5.23 % | $ 181 M | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
Galapagos NV
GLPG
|
709 M | $ 32.94 | -3.37 % | $ 2.69 B | ||
|
Greenwich LifeSciences
GLSI
|
16 M | $ 27.32 | -0.27 % | $ 356 M | ||
|
Galecto
GLTO
|
39.9 M | $ 29.84 | -0.7 % | $ 793 M | ||
|
Genmab A/S
GMAB
|
67.9 M | $ 27.53 | -7.17 % | $ 17.6 B | ||
|
Gossamer Bio
GOSS
|
184 M | $ 0.46 | 8.47 % | $ 70.2 M | ||
|
GeoVax Labs
GOVX
|
26.7 M | $ 1.53 | -1.92 % | $ 2.78 M | ||
|
Grifols, S.A.
GRFS
|
1.64 B | $ 8.54 | -6.11 % | $ 6.83 B | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
Halozyme Therapeutics
HALO
|
218 M | $ 69.01 | -1.2 % | $ 8.27 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
46 M | $ 3.17 | -5.09 % | $ 1.13 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
Hoth Therapeutics
HOTH
|
8.22 M | $ 0.99 | -2.47 % | $ 6.31 M | ||
|
Agios Pharmaceuticals
AGIO
|
543 M | $ 28.49 | -2.57 % | $ 1.65 B | ||
|
Harmony Biosciences Holdings
HRMY
|
462 M | $ 28.56 | -1.18 % | $ 1.64 B | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M |